Elucid Raises $27 Million Series B Funding Round to Commercialize a New Paradigm in Heart Disease Diagnosis
BOSTON, June 22, 2022 /PRNewswire/ -- Elucid, a company developing a novel, non-invasive medical software to comprehensively characterize cardiovascular disease,...